SEBI examines Sun, Ranbaxy merger trading - source

MUMBAI Wed Apr 9, 2014 8:12pm IST

A general view of the office of Ranbaxy Laboratories is pictured at Gurgaon, on the outskirts of New Delhi, June 13, 2013. REUTERS/Adnan Abidi/Files

A general view of the office of Ranbaxy Laboratories is pictured at Gurgaon, on the outskirts of New Delhi, June 13, 2013.

Credit: Reuters/Adnan Abidi/Files

Related Topics

Stocks

   

MUMBAI (Reuters) - The Securities and Exchange Board of India (SEBI) will ask Ranbaxy Laboratories and Sun Pharmaceutical Industries for more information about their planned $3.2 billion merger and seek trading data from stock exchanges after shares in Ranbaxy surged in the run-up to the deal, a senior source at the regulator said on Wednesday.

Ranbaxy (RANB.NS) shares jumped 24 percent while trading volume tripled in the three sessions ahead of Monday's announcement that Sun Pharma (SUN.NS) would buy it in what would be the biggest drug sector deal in the Asia-Pacific region this year.

"We have received multiple complaints. We will ask stock exchanges on details of buy and sell trades in both Ranbaxy and Sun shares," said SEBI source, who declined to be identified because he is not authorised to speak with the media on the matter.

The official added that SEBI would also ask for "additional disclosures" from the two drug makers.

Sun's managing director, Dilip Shanghvi, said India's largest drug maker by market value had not received any inquiries from SEBI in an interview with CNBC-TV 18.

"We haven't heard (from the regulator)," Shanghvi said on Wednesday afternoon.

"We also have concern about the run-up in Ranbaxy stock a few days before the transaction was announced, but we hope that nothing comes out of that inquiry."

Spokesmen for SEBI and Ranbaxy declined to comment. The National Stock Exchange of India Ltd and BSE Ltd, India's two biggest exchanges, also declined to comment.

The president of a brokerage association said it would formally ask the regulator to investigate trading in Ranbaxy's shares.

"Because there was such kind of price movement before the deal was announced, we have decided to check with the regulator," Naresh Tejwani, president of the Association of National Exchanges Members of India (ANMI), said on Wednesday.

The stock markets have seen previous cases of sudden sharp movements in company shares ahead of big corporate announcements, raising frequent suspicion about insider trading that have damaged retail investor confidence.

For example, last June, Infosys Ltd's (INFY.NS) shares and option volumes surged before the surprise announcement that founder Narayan Murthy was returning as executive chairman.

The regulator has been accused by some market participants of being slow to investigate suspected insider trading and ill-equipped to fight securities fraud. Its investigations can take years and are often conducted in secrecy.

Like other global regulators, SEBI has often resorted to fines and settlements, which are easier to obtain than criminal indictments.

Its most high profile case so far has been investigating a unit of energy conglomerate Reliance Industries Ltd (RELI.NS) over a suspected case of insider trading in 2007.

After six years of investigation, SEBI last year fined Reliance 110 million Indian rupees, saying it had found enough evidence of insider trading. The energy company, which had net profit of 55.1 billion rupees in the October-December quarter, is appealing to SEBI's appellate body.

The regulator is expected to debut new insider trading rules later this year that would require executives to disclose planned trading activity and also require companies to monitor their employees for trading.

Retail investors have been heavy sellers in Indian markets and have redeemed about $5.2 billion from equity funds in India since 2010.

The

(Additional reporting by Abhishek Vishnoi; editing by Tony Munroe and Tom Pfeiffer)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

Health Reforms

REUTERS SHOWCASE

Record Highs

Record Highs

Nifty touches record high; software stocks gain.  Full Article 

New Adviser

New Adviser

Arvind Subramanian likely to be chief econ adviser.  Full Article 

Pricing Mechanism

Pricing Mechanism

Govt sets up a four-member panel to re-examine gas pricing.  Full Article 

Royalty Rates

Royalty Rates

India to hike iron ore royalty, miners may struggle to pass on extra cost.  Full Article 

Diesel Deregulation

Diesel Deregulation

Oil ministry to seek Cabinet nod on diesel deregulation - sources  Full Article 

Commodities

Commodities

Gold near two-month low; set for weekly drop on interest rate fears  Full Article 

Reuters Exclusive

Reuters Exclusive

Apple iPhone 6 screen snag leaves supply chain scrambling   Full Article 

Helping Regional Mills

Helping Regional Mills

Govt raises sugar import duty to 25 pct from 15 pct.  Full Article 

Curbing Risks

Curbing Risks

RBI to lower ceiling on bank loans to a single corporate group.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage